| GEN |
Report |
Non-GAAP revenue |
BEAT |
pred ~$1.327B vs. cons $1.313B |
MEDIUM |
| GEN |
Report |
Non-GAAP diluted EPS |
BEAT |
pred ~$0.71 vs. cons $0.69 |
MEDIUM |
| GEN |
Report |
Bookings |
BEAT |
pred ~$1.414B vs. cons $1.395B |
LOW |
| GEN |
Guide |
FY27 non-GAAP revenue guidance |
LOWER |
guide ~$5.375B vs. cons $5.390B (FY27) |
MEDIUM |
| GEN |
Guide |
FY27 non-GAAP EPS guidance |
LOWER |
guide ~$2.90 vs. cons $2.92 (FY27) |
MEDIUM |
| GEN |
Guide |
FY27 Q2 non-GAAP revenue guidance |
LOWER |
guide ~$1.330B vs. cons $1.340B (FY27 Q2) |
LOW |
| GEN |
Guide |
FY27 Q2 non-GAAP EPS guidance |
LOWER |
guide ~$0.71 vs. cons $0.72 (FY27 Q2) |
LOW |
| GEN |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.0% |
— |
MEDIUM |
| GEN |
Return |
5-day cumulative residual |
-5.0% (FOLLOW-THROUGH) |
A Q1 beat of ~$1.327B revenue versus ~$1.313B consensus and ~$0.71 EPS versus ~$0.69 consensus is likely outweighed by FY27 guide math of ~$5.375B versus ~$5.390B and ~$2.90 EPS versus ~$2.92 consensus; unchanged company ranges would imply modest out-period estimate cuts after an already strong pre-print move. |
MEDIUM |